Contribution of Cytochrome P450 and ABCB1 Genetic Variability on Methadone Pharmacokinetics, Dose Requirements, and Response Pharmacogenetics and Methadone Treatment Response
2011

Genetic Factors Affecting Methadone Treatment Response

Sample size: 105 publication Evidence: moderate

Author Information

Author(s): Fonseca Francina, de la Torre Rafael, Díaz Laura, Pastor Antonio, Cuyàs Elisabet, Pizarro Nieves, Khymenets Olha, Farré Magí, Torrens Marta

Primary Institution: Institut de Neuropsiquiatria i Addiccions - Parc de Salut Mar, Barcelona, Spain

Hypothesis

The study aims to analyze methadone dosage in responder and nonresponder patients considering pharmacogenetic and pharmacokinetic factors that may contribute to dosage adequacy.

Conclusion

The study found that genetic polymorphisms related to methadone metabolism have little influence on treatment outcomes, with significant differences in methadone dosage between responders and nonresponders.

Supporting Evidence

  • Responder patients received higher doses of methadone and had been in treatment longer than nonresponders.
  • Only CYP2D6 metabolizing phenotype differences were found in outcome status, methadone dose requirements, and plasma concentrations.
  • Genetic polymorphisms in CYP3A5, CYP2B6, CYP2C9, CYP2C19, and ABCB1 did not significantly influence methadone dosage.

Takeaway

Some people need more medicine to feel better, and this study looked at how genes might affect how much medicine people need when they are trying to stop using drugs.

Methodology

The study recruited opioid dependence patients from a community program, assessed their clinical status, and analyzed blood samples for methadone concentrations and genetic variants.

Potential Biases

Patients with poorer outcomes may have been underrepresented due to reluctance to participate in the study.

Limitations

The sample size was small, and patients with poorer outcomes were less likely to participate, which may introduce bias.

Participant Demographics

The final sample consisted of 105 opioid dependent patients of Caucasian origin, with a mean age of 38 years and 71% male.

Statistical Information

P-Value

0.007

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0019527

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication